Table 4.
Selected adverse events and laboratory abnormalities from phase 2/3 studies.
| Lapatinib20,46 | Neratinib20 | Pyrotinib18 | Tucatinib19 | |||||
|---|---|---|---|---|---|---|---|---|
| Grade | Any (%) | ≥3 (%) | Any (%) | ≥3 (%) | Any (%) | ≥3 (%) | Any (%) | ≥3 (%) |
| Gastrointestinal | ||||||||
| Diarrhea | 60 | 13 | 83 | 24 | 97 | 15 | 81 | 13 |
| Nausea | 44 | 4 | 53 | 4 | 39 | 2 | 58 | 4 |
| Vomiting | 26 | 2 | 46 | 4 | 62 | 5 | 36 | 3 |
| Stomatitis | 15 | 0 | 21 | 2 | 11 | 0 | 26 | 3 |
| Anorexia | 15 | 1 | 35 | 3 | 32 | 2 | 25 | 1 |
| Increased AST | 51 | – | 6 | 1 | 26 | 3 | 21 | 5 |
| Increased ALT | 42 | – | 10 | 1 | 29 | 2 | 20 | 5 |
| Mucocutaneus | ||||||||
| PPE syndrome | 49 | 7 | 46 | 10 | 79 | 26 | 63 | 13 |
| Rash | 27 | 1 | 10 | 0 | 5 | 2 | 20 | – |
| Cardiovascular | ||||||||
| Decreased LVEF | 2 | 1 | 4 | 0 | – | – | – | – |
| Other | ||||||||
| Headache | 9 | 0 | 11 | 0 | – | – | 22 | 1 |
| Anemia | 16 | 4 | 15 | 2 | 22 | 2 | – | – |
| Pyrexia | 16 | 1 | 11 | 0 | 9 | 0 | – | – |
AST aspartate aminotransferase, ALT alanine aminotransferase, PPE palmar plantar erythrodysesthesia, LVEF left ventricular ejection fraction.